PF 4064900Alternative Names: PF-4064900
Latest Information Update: 12 Aug 2009
At a glance
- Originator Pfizer
- Class Antibacterials
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Bacterial infections in USA (unspecified route)
- 30 Sep 2008 Phase-I clinical trials in Bacterial infections in USA (unspecified route)